We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
- Authors
Rochigneux, Philippe; Thomassin-Piana, Jeanne; Laibe, Sophy; Brunelle, Serge; Salem, Naji; Escudier, Bernard; Vassal, Gilles; Gravis, Gwenaelle
- Abstract
<bold>Background: </bold>Papillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma. It has a poorer prognosis than clear cell RCC (ccRCC) with a lack of standard treatments.<bold>Case Presentation: </bold>We report the case of a 51 year old man with a metastatic pRCC (hepatic dome and left colonic peritoneal carcinomatosis) progressive after sunitinib, with a MET amplification. The patient was enrolled in the UNICANCER-sponsored AcSé crizotinib trial (NCT02034981), designed to give an access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug. With 2nd line crizotinib (250 mg twice/day), the patient had a very good tolerance, a partial response in the target lesions using RECIST 1.1, and a 19 months' clinical efficacy.<bold>Conclusions: </bold>In metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option.
- Subjects
CRIZOTINIB; RENAL cell carcinoma; DRUG efficacy; GENE amplification; CANCER prognosis; CANCER treatment
- Publication
BMC Cancer, 2018, Vol 18, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-018-5049-3